| dc.contributor.author | Gaikwad, Anil Bhanudas | |
| dc.date.accessioned | 2025-03-17T04:39:21Z | |
| dc.date.available | 2025-03-17T04:39:21Z | |
| dc.date.issued | 2024-10 | |
| dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/13543784.2024.2417755 | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18383 | |
| dc.description.abstract | To improve kidney disease treatments, it is crucial to understand how inflammaging affects patients´ longevity. We could potentially slow down kidney disease progression and enhance longevity by targeting specific pathways involved in inflammaging with potential drugs. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Autophagy | en_US |
| dc.subject | Caloric restriction | en_US |
| dc.subject | Inflammaging | en_US |
| dc.subject | Kidney diseases | en_US |
| dc.subject | Metabolic dysregulation | en_US |
| dc.title | Management of inflammaging in kidney diseases: focusing on the current investigational drugs | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||